Drug intelligence / Profile preview

Recombinant Human Chymotrypsin

Development stage: Phase 2
Lead developer: Wuhan Healthgen Biotechnology
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral, Intrathoracically

Overview

Recombinant Human Chymotrypsin (OsrhCT) is a freeze-dried powder developed by Wuhan Healthgen Biotechnology Corporation. It is a proteolytic enzyme being investigated for its therapeutic potential. Clinical trials are evaluating its efficacy as a premedication to improve gastric mucosa visibility during upper gastrointestinal endoscopy and for intrathoracic administration in patients with pleurisy.

Brand names: OsrhCT
Other names: recombinant human chymotrypsin

Targets

PSMB5 (Proteasome subunit beta Type-5)

Beyond the preview

Go deeper on Recombinant Human Chymotrypsin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recombinant Human Chymotrypsin.

Explore the full profile